Radiopharm Theranostics (Radiopharm Theranostics) Other Operating Expense : $5.30 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics Other Operating Expense?

Radiopharm Theranostics's Other Operating Expense for the six months ended in Dec. 2023 was $1.05 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was $5.30 Mil.

Radiopharm Theranostics's quarterly Other Operating Expense increased from Dec. 2022 ($1.11 Mil) to Jun. 2023 ($4.25 Mil) but then declined from Jun. 2023 ($4.25 Mil) to Dec. 2023 ($1.05 Mil).

Radiopharm Theranostics's annual Other Operating Expense increased from . 20 ($0.00 Mil) to Jun. 2022 ($3.48 Mil) and increased from Jun. 2022 ($3.48 Mil) to Jun. 2023 ($5.36 Mil).

Radiopharm Theranostics Other Operating Expense Historical Data

The historical data trend for Radiopharm Theranostics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Other Operating Expense Chart

Radiopharm Theranostics Annual Data

Trend

Jun22

Jun23

Other Operating Expense

3.48

5.36

Radiopharm Theranostics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Other Operating Expense	0.98	2.52	1.11	4.25	1.05

Radiopharm Theranostics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $5.30 Mil.

Radiopharm Theranostics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Radiopharm Theranostics (Radiopharm Theranostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

RAD:Australia

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.radiopharmtheranostics.com

Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (Radiopharm Theranostics) Headlines

From GuruFocus

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 07-10-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-10-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-20-2022

RADIOPHARM ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND ASSUMES PD-L1 LICENSING AGREEMENT FROM NANOMAB

By PRNewswire PRNewswire • 08-04-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-30-2022

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire • 10-19-2022